FK506-binding protein 12 fusion protein (FKBP12 fusion)

FK506-binding protein 12 (FKBP12) fusion proteins are synthetic, engineered molecules designed to provide precise pharmacological control over cellular processes (patsnap.com, nih.gov). These proteins typically consist of a modified FKBP12 domain, such as the F36V 'hole' mutant, fused to a functional effector protein like the catalytic domain of Caspase 9 (iCasp9) (nih.gov, researchgate.net). This system serves as a 'safety switch' in adoptive cell therapies; upon administration of a small-molecule dimerizer like rimiducid (AP1903), the fusion proteins homodimerize, activating the Caspase 9 cascade and inducing rapid apoptosis to eliminate engineered cells in the event of severe toxicity (nih.gov, medchemexpress.com). Beyond suicide switches, FKBP12 fusions are central to the degradation TAG (dTAG) system, where heterobifunctional degraders recruit E3 ligases to the fusion protein to trigger its proteasomal degradation (nih.gov, mdpi.com). The versatility of the FKBP12 domain also allows for the regulation of signal transduction and protein localization through chemically induced dimerization (CID) (wikipedia.org, pnas.org). By utilizing 'bump-and-hole' engineering, these fusion proteins can be selectively targeted by synthetic ligands that do not interact with endogenous wild-type FKBP12, thereby minimizing off-target effects (medchemexpress.com, nih.gov). This technology has become a cornerstone for developing safer and more controllable cell-based immunotherapies and functional genomics tools (ailurus.bio, nih.gov).

Other names

iCasp9Inducible Caspase 9FKBP12-F36V fusionFKBP12-Caspase 9dTAG fusionSuicide gene switchInducible Caspase 9 (iCasp9)

Chemically induced dimerization (CID) leading to effector activation (e.g., Caspase 9) or recruitment of E3 ubiquitin ligases for targeted protein degradation (TPD).